N-methylnaltrexone bromide (MOA-728)

DRUG3 trials

Sponsors

Bausch Health Americas, Inc.

Conditions

Constipation

Phase 2

Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain

CompletedNCT00547586

Bausch Health Americas, Inc.Constipation

Start: 2007-10-31End: 2008-02-29Updated: 2020-08-20

Phase 3

Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

CompletedNCT00529087

Bausch Health Americas, Inc.Constipation

Start: 2007-08-31End: 2008-12-31Updated: 2019-11-25

Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation

CompletedNCT00804141

Bausch Health Americas, Inc.Constipation

Start: 2008-12-03End: 2010-09-20Updated: 2019-10-18

Related Papers

The Influence of Age on Central Effects of Methylnaltrexone in Patients with Opioid-Induced Constipation.

2021-03-314 citations